Time-resolved immune dynamics in rheumatoid arthritis under methotrexate therapy

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Methotrexate (MTX) is a primary treatment for rheumatoid arthritis (RA).
• The precise immunological mechanisms of MTX action are not fully understood.
• Defining these mechanisms is crucial for optimizing RA treatment.

Purpose of the Study:

• To elucidate the time-resolved cellular and molecular changes induced by MTX in RA patients.
• To identify early indicators of MTX treatment efficacy.
• To understand the immunological basis of MTX response in RA.

Main Methods:

• A prospective longitudinal study involving newly diagnosed RA patients initiating MTX.
• Integrated single-cell multiomics (immunophenotyping and RNA sequencing) of peripheral blood mononuclear cells (PBMCs).
• In vitro functional assays and validation in independent patient cohorts and external datasets.

Main Results:

• MTX induced rapid immune remodeling detectable by 3 weeks, preceding clinical improvement.
• Selective decline in T follicular helper (Tfh) cells and plasmablasts observed in clinical responders.
• These cell populations and novel regulatory hubs (e.g., LMNA, GIMAP family) were identified as potential early biomarkers of MTX response.

Conclusions:

• MTX triggers a rapid and coordinated immune system reconfiguration in RA.
• Early alterations in Tfh cells and plasmablasts serve as predictive biomarkers for MTX treatment response.
• These findings enhance understanding of MTX's immunological effects and guide personalized RA therapy.